

## PE anti-mouse IFN- $\gamma$ Antibody

<b>Catalog# / Size</b>	505807 / 25 $\mu$ g 505808 / 100 $\mu$ g
<b>Clone</b>	XMG1.2
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Interferon- $\gamma$ , Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
<b>Isotype</b>	Rat IgG1, $\kappa$
<b>Description</b>	IFN- $\gamma$ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN- $\gamma$ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- $\gamma$ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	<i>E. coli</i> -expressed, recombinant mouse IFN- $\gamma$
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The IFN- $\gamma$ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">ICFC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">intracellular immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is $\leq 0.25$ $\mu$ g per million cells in 100 $\mu$ l volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	<p><b>ELISA<sup>1-4,11,14</sup> or ELISPOT<sup>5</sup> Detection:</b> The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-<math>\gamma</math> (Cat. No. 575309) as the standard.</p> <p><b>ELISA or ELISPOT Capture:</b> The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-<math>\gamma</math> (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).</p> <p><b>Flow Cytometry<sup>7,8,12,13,16</sup>:</b> The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-<math>\gamma</math>-producing cells within mixed cell populations.</p> <p><b>Neutralization<sup>1-3,9,10</sup>:</b> The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-<math>\gamma</math>. The LEAF™ purified antibody (Endotoxin &lt;0.1 EU/<math>\mu</math>g, Azide-Free, 0.2 <math>\mu</math>m filtered) is recommended for neutralization of mouse IFN-<math>\gamma</math> bioactivity <i>in vivo</i> and <i>in vitro</i> (Cat. No. 505812). For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin &lt;0.01 EU/<math>\mu</math>g).</p> <p><b>Additional reported applications (for the relevant formats) include:</b> Western blotting, immunohistochemical staining of frozen tissue sections<sup>6,22,23</sup>, and immunocytochemistry.</p>

**Note:** For testing mouse IFN- $\gamma$  in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

## Application References

1. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5. (ELISA, Neut)
2. Sander B, *et al.* 1993. *J. Immunol. Meth.* 166:201. (ELISA, Neut)
3. Abrams J, *et al.* 1995. *Curr. Prot. Immunol.* John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, *et al.* 1993. *J. Immunoassay* 14:129. (ELISA)
5. Klinman D, *et al.* 1994. *Curr. Prot. Immunol.* John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, *et al.* 1991. *Immunol. Rev.* 119:65. (IHC)
7. Ferrick D, *et al.* 1995. *Nature* 373:255. (FC)
8. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
9. Peterson KE, *et al.* 2000. *J. Virol.* 74:5363. (Neut)
10. DeKrey GK, *et al.* 1998. *Infect. Immun.* 66:827. (Neut)
11. Dzhagalov I, *et al.* 2007. *J. Immunol.* 178:2113. (ELISA)
12. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366. (FC)
13. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181. (FC) [PubMed](#)
14. Xu G, *et al.* 2007. *J. Immunol.* 179:5358. (ELISA) [PubMed](#)
15. Montfort M, *et al.* 2004. *J. Immunol.* 173:4084. [PubMed](#)
16. Haring JS, *et al.* 2008. *J. Immunol.* 180:2855. (FC) [PubMed](#)
17. Jordan JM, *et al.* 2008. *Infect Immun.* 76:3717. [PubMed](#)
18. Tonkin DR, *et al.* 2008. *J. Immunol.* 181:4516. [PubMed](#)
19. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
20. Cui Y, *et al.* 2009. *Invest. Ophthalm. Vis. Sci.* 50:5811. (FC) [PubMed](#)
21. Mykkanen OT, *et al.* 2014. *PLoS One.* 9:114790. [PubMed](#)
22. Yokogawa M, *et al.* 2013. *Mol. Carcinog.* 52:760. (IHC)
23. Mottram PL, *et al.* 1998. *J Immunol.* 161:602. (IHC)

## Product Citations

1. Wang H, *et al.* 2013. *J Immunol.* 191:6010. [PubMed](#)
2. Kim K, *et al.* 2016. *PLoS One.* 11: 0148576. [PubMed](#)
3. Liu Y, *et al.* 2021. *Cell Metabolism.* 33(6):1221-1233.e11. [PubMed](#)
4. Chen Y, *et al.* 2020. *Virology.* [PubMed](#)
5. Bradley CP *et al.* 2017. *Cell host & microbe.* 22(5):697-704. [PubMed](#)
6. Wu J *et al.* 2017. *Immunity.* 47(6):1114-1128. [PubMed](#)
7. Toubai T, *et al.* 2017. *Blood Adv.* 1.095138889. [PubMed](#)
8. Yu X, *et al.* 2020. *Nat Commun.* 11:1110. [PubMed](#)
9. Sandu I, *et al.* 2020. *Nat Commun.* 11:4454. [PubMed](#)
10. Wu MJ, *et al.* 2022. *Cancer Discov.* 12:812. [PubMed](#)
11. Tan L, *et al.* 2022. *Aging Dis.* 13:1562. [PubMed](#)
12. Gern BH, *et al.* 2021. *Cell Host Microbe.* 29(4):594-606.e6. [PubMed](#)
13. Lin W, *et al.* 2020. *Theranostics.* 10:4871. [PubMed](#)
14. Zhou J, *et al.* 2019. *Immunity.* 50:403. [PubMed](#)
15. Shi L, *et al.* 2019. *Theranostics.* 9:4115. [PubMed](#)
16. Alissafi T, *et al.* 2018. *J Clin Invest.* 128:3840. [PubMed](#)
17. Li X, *et al.* 2022. *Nat Commun.* 13:2794. [PubMed](#)
18. Zhou J, *et al.* 2021. *Int J Med Sci.* 18:3516. [PubMed](#)
19. Kim D, *et al.* 2021. *Nanomedicine Lett.* 13:31. [PubMed](#)
20. Xia S, *et al.* 2014. *J Leukoc Biol.* 95:733. [PubMed](#)
21. Su N, Xiong Y 2016. *Sci Rep.* 6:22658. [PubMed](#)
22. Dong L, *et al.* 2021. *Cancer Cell.* [PubMed](#)
23. Gálvez-Cancino F, *et al.* 2017. *Vaccine.* 10.1016/j.vaccine.2017.06.041. [PubMed](#)
24. Wang X, *et al.* 2018. *Int Immunopharmacol.* 56:249. [PubMed](#)
25. Liu QZ, *et al.* 2018. *Front Immunol.* 1.131944444. [PubMed](#)
26. Yang F, *et al.* 2021. *Front Microbiol.* 11:512581. [PubMed](#)
27. Kiritsy MC, *et al.* 2021. *Elife.* 10:. [PubMed](#)
28. Stegelmeier AA, *et al.* 2022. *Biomedicine.* 10:. [PubMed](#)
29. Chen L, *et al.* 2022. *Mol Ther Oncolytics.* 24:522. [PubMed](#)
30. Liang S, *et al.* 2022. *Acta Pharm Sin B.* 12:2494. [PubMed](#)
31. Coleby R, *et al.* 2021. *Clin Exp Rheumatol.* :39. [PubMed](#)
32. Zhang S, *et al.* 2022. *Cell Death Dis.* 13:844. [PubMed](#)
33. Tang Y, *et al.* 2020. *Front Immunol.* 11:585918. [PubMed](#)
34. Chakrabarti J, *et al.* 2018. *Oncotarget.* 9:37439. [PubMed](#)
35. Oyarce C, *et al.* 2018. *Front Immunol.* 8:1794. [PubMed](#)
36. Mayer RL, *et al.* 2022. *Nat Commun.* 13:6075. [PubMed](#)
37. Snyder LM, *et al.* 2021. *PLoS Pathog.* 17:e1009970. [PubMed](#)
38. Nagatake T, *et al.* 2022. *Mucosal Immunol.* 15:289. [PubMed](#)
39. Herman JD, *et al.* 2021. *Nat Commun.* 12:6853. [PubMed](#)
40. Galeano Niño JL, *et al.* 2020. *J Cell Sci.* [PubMed](#)
41. Saito S, *et al.* 2020. *Nutrients.* 12:. [PubMed](#)
42. Koenecke C, *et al.* 2012. *J Immunol.* 189:2890. [PubMed](#)
43. Michel M, *et al.* 2012. *Proc Natl Acad Sci U S A.* 109:17459. [PubMed](#)
44. Wang Y, *et al.* 2016. *Sci Rep.* 6:31881. [PubMed](#)
45. Chen D, *et al.* 2018. *Nat Commun.* 9:873. [PubMed](#)
46. Papafragkos I, *et al.* 2022. *Front Immunol.* 13:889075. [PubMed](#)
47. Xiong A, *et al.* 2022. *EBioMedicine.* 83:104239. [PubMed](#)
48. Lv H, *et al.* 2020. *Cell Metabolism.* 33(1):110-127.e5. [PubMed](#)
49. Alissafi T, *et al.* 2020. *Cell Metabolism.* 32(4):591-604.e7. [PubMed](#)

50. Sharma S, *et al.* 2015. J Immunol. 194:5529. [PubMed](#)
51. Pan W *et al.* 2017. Immunity. 47(2):284-297 . [PubMed](#)
52. Ning X, *et al.* 2019. Mol Cell. 74:19. [PubMed](#)
53. Uchimura T *et al.* 2018. Immunity. 49(6):1049-1061 . [PubMed](#)
54. Dai B, *et al.* 2022. Theranostics. 12:7603. [PubMed](#)
55. Kuttke M, *et al.* 2022. Front Immunol. 13:695576. [PubMed](#)
56. Xu X, *et al.* 2021. J Nanobiotechnology. 19:376. [PubMed](#)
57. Subbiah J, *et al.* 2022. NPJ Vaccines. 7:68. [PubMed](#)
58. Wang C, *et al.* 2021. Cell Rep. 37:110021. [PubMed](#)
59. Wan Y, *et al.* 2014. Vaccine. 41:241. [PubMed](#)
60. Sandrock I, *et al.* 2015. PLoS One. 10: 0145010. [PubMed](#)
61. Koren N, *et al.* 2021. Cell Host Microbe. 29(2):197-209.e5. [PubMed](#)
62. Uchil PD *et al.* 2018. Cell host & microbe. 25(1):87-100 . [PubMed](#)
63. Probst P, *et al.* 2017. Cancer Res. 77:3644. [PubMed](#)
64. Caronni N, *et al.* 2018. Cancer Res. 78:1685. [PubMed](#)
65. An J, *et al.* 2022. iScience. 25:103570. [PubMed](#)
66. Han JP, *et al.* 2022. Sci Adv. 8:eabj6901. [PubMed](#)
67. Shami A, *et al.* 2015. Sci Rep. 5: 13904. [PubMed](#)
68. Gungor B, *et al.* 2014. Sci Transl Med. 6:235. [PubMed](#)
69. Hegde S, *et al.* 2020. Cancer Cell. 37(3):289-307. [PubMed](#)
70. Srey MT, *et al.* 2020. PLoS Negl Trop Dis. 14:e0008842. [PubMed](#)
71. Chen D, *et al.* 2022. J Neuroinflammation. 19:112. [PubMed](#)
72. Cha SE, *et al.* 2021. Oncoimmunology. 10:1899469. [PubMed](#)
73. Canton J, *et al.* 2021. Nat Immunol. 22:140. [PubMed](#)
74. Cho K, Hill A 2008. J Immunol Methods. 330:137. [PubMed](#)
75. Condotta S, *et al.* 2015. J Immunol. 195: 116 - 125. [PubMed](#)
76. Satoh M, *et al.* 2016. Sci Rep. 6:28473. [PubMed](#)
77. Gong Y, *et al.* 2020. Cell Metabolism. 33(1):51-64.e9. [PubMed](#)
78. Espinosa JR, *et al.* 2018. Front Immunol. 9:1371. [PubMed](#)
79. Hundt M, *et al.* 2009. J Immunol. 183:1685. [PubMed](#)
80. Duan RN, *et al.* 2021. J Neuroinflammation. 18:145. [PubMed](#)
81. Hanasoge Somasundara AV, *et al.* 2021. Cell Rep. 37:110099. [PubMed](#)
82. Cheng B, *et al.* 2022. Cancer Commun (Lond). 42:17. [PubMed](#)
83. Brigas HC, *et al.* 2021. Cell Reports. 36(9):109574. [PubMed](#)
84. Sartorius R, *et al.* 2015. EMBO Mol Med. 7: 973 - 988. [PubMed](#)
85. Miranda AC, *et al.* 2020. Oncoimmunology. 9:1760685. [PubMed](#)
86. Garo LP, *et al.* 2019. Cell Rep. 28:3353. [PubMed](#)
87. Li W, *et al.* 2019. Nat Commun. 10:3349. [PubMed](#)
88. Yan Y, *et al.* 2018. JCI Insight. 3. [PubMed](#)
89. Place D, *et al.* 2017. PLoS One. 10.1371/journal.pone.0190384. [PubMed](#)
90. Palazon A, *et al.* 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. [PubMed](#)
91. Reese B, *et al.* 2020. J Immunol. 205:3218. [PubMed](#)
92. Ma Y, *et al.* 2013. J Immunol. 190:5588. [PubMed](#)
93. Dutow P, *et al.* 2014. J Infect Dis. 209:1269. [PubMed](#)
94. QT N, *et al.* 2015. Antimicrob Agents Chemother. 59: 6308-6316. [PubMed](#)
95. Latasa C, *et al.* 2016. PLoS One. 11: 0161216. [PubMed](#)
96. Holokai L, *et al.* 2020. Cancers (Basel). 12:00. [PubMed](#)
97. Galeano Niño JL, *et al.* 2020. J Cell Sci. 133:00:00. [PubMed](#)
98. Vaena S, *et al.* 2021. Cell Reports. 35(5):109076. [PubMed](#)
99. Marcus A *et al.* 2018. Immunity. 49(4):754-763 . [PubMed](#)
100. Bosnjak B, *et al.* 2021. Front Immunol. 12:772240. [PubMed](#)
101. Tian X, *et al.* 2022. J Cell Mol Med. 26:693. [PubMed](#)
102. Yan J, *et al.* 2020. Cell Rep. 107820:31. [PubMed](#)
103. Shen JZ, *et al.* 2020. Cell. 184(2):352-369.e23. [PubMed](#)
104. Ren Y, *et al.* 2015. Sci Rep. 5: 18099. [PubMed](#)
105. Kraus Z, *et al.* 2008. J Immunol. 181:7800. [PubMed](#)
106. Lin W, *et al.* 2019. EBioMedicine. 49:133. [PubMed](#)
107. Leclerc M, *et al.* 2019. Nat Commun. 10:3345. [PubMed](#)
108. Nagatake T, *et al.* 2018. Int Immunol. 30:471. [PubMed](#)
109. Chatterjee S *et al.* 2017. Cell metabolism. 27(1):85-100 . [PubMed](#)
110. Yang Z, *et al.* 2021. Onco Targets Ther. 14:4239. [PubMed](#)
111. De Ponte Conti B, *et al.* 2021. Elife. 10:. [PubMed](#)
112. Tanaka Y, *et al.* 2020. Sci Rep. 10:17284. [PubMed](#)
113. Ohtsuka J, *et al.* 2021. iScience. Online ahead of print. [PubMed](#)
114. Lu J, *et al.* 2021. Cell Death Discov. 7:165. [PubMed](#)
115. Koelwyn GJ, *et al.* 2020. Nat Med. 1452:26. [PubMed](#)
116. Karandikar SH, *et al.* 2019. JCI Insight. 5. [PubMed](#)
117. Bartolacci C, *et al.* 2018. Cancer Immunol Res. 1.281944444. [PubMed](#)
118. Montfort M, *et al.* 2004. J Immunol. 173:4084. [PubMed](#)
119. Xu P, *et al.* 2020. Cancer Immunol Res. 8:1193. [PubMed](#)
120. Xu Q, *et al.* 2021. Theranostics. 11:1937. [PubMed](#)
121. Guo S, *et al.* 2021. Sci Rep. 11:23745. [PubMed](#)
122. Hirata SI, *et al.* 2020. Allergy. 75:1939. [PubMed](#)
123. Castiglioni P, *et al.* 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. [PubMed](#)
124. Kalafati L, *et al.* 2020. Cell. 183:771. [PubMed](#)
125. Roy S, *et al.* 2019. Front Immunol. 2.404166667. [PubMed](#)
126. Yuan X, *et al.* 2017. Elife. 6:e29540. [PubMed](#)
127. Nagatake T, *et al.* 2018. J Allergy Clin Immunol. 142:470. [PubMed](#)
128. Zhang J, *et al.* 2018. Nature. 553:91. [PubMed](#)
129. Dong M, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)

130. Ye Q, *et al.* 2022. NPJ Vaccines. 7:84. [PubMed](#)
131. Stephens WZ, *et al.* 2021. Cell Rep. 37:109916. [PubMed](#)
132. Wang Y, *et al.* 2020. Virol Sin. 36:122. [PubMed](#)
133. Miura N, *et al.* 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. [PubMed](#)
134. Miao W, *et al.* 2020. J Immunol. 1486:204. [PubMed](#)
135. Raju S, *et al.* 2020. Cell Reports. 29(9):2556-2564.e3.. [PubMed](#)
136. Mandour MF, *et al.* 2020. Infect Agent Cancer. 15:30. [PubMed](#)
137. Cartwright ANR, *et al.* 2021. Cancer Immunol Res. 9:470. [PubMed](#)
138. Li H, *et al.* 2021. Front Immunol. 12:739605. [PubMed](#)
139. Kiritsy MC, *et al.* 2021. Elife. 10:. [PubMed](#)
140. Mah-Som AY, *et al.* 2021. Cell Reports. 35(9):109209. [PubMed](#)
141. Lee J, *et al.* 2007. Nat Immunol. 8:181. [PubMed](#)
142. Tian D, *et al.* 2019. Nat Commun. 10:4246. [PubMed](#)
143. Ma Q, *et al.* 2022. Vaccines (Basel). 10:. [PubMed](#)
144. Kim MY, *et al.* 2022. Nat Commun. 13:3296. [PubMed](#)
145. Johnson RM, *et al.* 2021. Front Immunol. 11:614697. [PubMed](#)
146. Hoechst B, *et al.* 2016. J Immunol. 195:1517-1523. [PubMed](#)
147. Ding L *et al.* 2018. Cell reports. 25(11):2972-2980 . [PubMed](#)
148. Tomaru U *et al.* 2019. Cell reports. 26(3):639-651 . [PubMed](#)
149. Molgora M, *et al.* 2020. Cell. 182:886. [PubMed](#)
150. Fang W, *et al.* 2021. J Exp Clin Cancer Res. 40:4. [PubMed](#)
151. Chen L, *et al.* 2021. Theranostics. 11:6668. [PubMed](#)
152. Rousso-Noori L, *et al.* 2021. Nat Commun. 12:3615. [PubMed](#)
153. Wang Y, *et al.* 2021. Front Immunol. 11:601601. [PubMed](#)
154. Prakash MD, *et al.* 2021. PLoS One. 16:e0247492. [PubMed](#)
155. Zhang X, *et al.* 2020. J Cancer. 11:648. [PubMed](#)
156. Zhao K, *et al.* 2021. Biomed Res Int. 7619849:2020. [PubMed](#)
157. Charlton J, *et al.* 2015. PLoS One. 10:119200. [PubMed](#)
158. Chakraborty P, *et al.* 2020. Cell Reports. 28(7):1879-1893.e7.. [PubMed](#)
159. Nakao R, *et al.* 2022. NPJ Vaccines. 7:153. [PubMed](#)
160. McAusland TM, *et al.* 2021. Mol Ther Oncolytics. 20:306. [PubMed](#)
161. Li H, *et al.* 2022. iScience. 25:104481. [PubMed](#)
162. Zhang X, *et al.* 2021. Front Pharmacol. 12:706748. [PubMed](#)
163. Liu X, *et al.* 2021. Adv Sci (Weinh). 8:e2100233. [PubMed](#)
164. Gaylo A, *et al.* 2013. Transpl Immunol. 20:163. [PubMed](#)
165. Timilshina M, *et al.* 2020. Cell Reports. 27(10):2948-2961.e7.. [PubMed](#)
166. Kim YS, *et al.* 2018. Front Immunol. 9:1093. [PubMed](#)
167. Wang N, *et al.* 2020. Front Immunol. 1.765972222. [PubMed](#)
168. Dourcy M, *et al.* 2020. Mucosal Immunol. 13:799. [PubMed](#)
169. Kerdidani D, *et al.* 2022. J Exp Med. 219:. [PubMed](#)
170. Zheng Y, *et al.* 2022. Transl Res. .: [PubMed](#)
171. Nabekura T, *et al.* 2020. Immunity. 96:52. [PubMed](#)
172. Chow AK, *et al.* 2021. Cellular and Molecular Gastroenterology and Hepatology. .: [PubMed](#)
173. Tripathi D, *et al.* 2016. Nat Commun. 7:13896. [PubMed](#)
174. Brenner E, *et al.* 2020. Nat Commun. 11:1335. [PubMed](#)
175. Qi S, *et al.* 2020. Theranostics. 10:1814. [PubMed](#)
176. Chen S, *et al.* 2018. Nat Commun. 9:5298. [PubMed](#)
177. Bing Wu *et al.* 2018. Immunity. 49(5):886-898 . [PubMed](#)
178. Chen PM, *et al.* 2022. Sci Adv. 8:eabo4271. [PubMed](#)
179. Song X, *et al.* 2022. Transl Oncol. 15:101306. [PubMed](#)
180. Yang F, *et al.* 2021. Nat Commun. 12:3424. [PubMed](#)
181. Li X, *et al.* 2021. Front Cell Dev Biol. 9:647713. [PubMed](#)

RRID AB\_315401 (BioLegend Cat. No. 505807)  
 AB\_315402 (BioLegend Cat. No. 505808)

## Antigen Details

---

<b>Structure</b>	Cytokine; dimer; 40-80 kD (Mammalian)
<b>Bioactivity</b>	Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
<b>Cell Sources</b>	CD8 <sup>+</sup> and CD4 <sup>+</sup> T cells, NK cells
<b>Cell Targets</b>	T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
<b>Receptors</b>	IFN- $\gamma$ R $\alpha$ (CDw119) dimerized with IFN- $\gamma$ R $\beta$ (AF-1)
<b>Cell Type</b>	Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Neuroinflammation, Neuroscience
<b>Molecular Family</b>	Cytokines/Chemokines
<b>Antigen References</b>	1. Fitzgerald K, <i>et al.</i> Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.

- De Maeyer E, *et al.* 1992. *Curr. Opin. Immunol.* 4:321.
- Farrar M, *et al.* 1993. *Annu. Rev. Immunol.* 11:571.
- Gray P, *et al.* 1987. *Lymphokines* 13:151.

**Regulation** Upregulated by IL-2, FGF-basic, EGF; downregulated by 1- $\alpha$ -25-Dihydroxy vitamin D3, dexamethasone

**Gene ID** [15978](#)

## Related Protocols


[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse IFN- $\gamma$ , Biotin anti-mouse IFN- $\gamma$ , FITC anti-mouse IFN- $\gamma$ , PE anti-mouse IFN- $\gamma$ , Purified anti-mouse IFN- $\gamma$ , Alexa Fluor<sup>®</sup> 488 anti-mouse IFN- $\gamma$ , Alexa Fluor<sup>®</sup> 647 anti-mouse IFN- $\gamma$ , Pacific Blue<sup>™</sup> anti-mouse IFN- $\gamma$ , PerCP/Cyanine5.5 anti-mouse IFN- $\gamma$ , PE/Cyanine7 anti-mouse IFN- $\gamma$ , Brilliant Violet 421<sup>™</sup> anti-mouse IFN- $\gamma$ , Brilliant Violet 650<sup>™</sup> anti-mouse IFN- $\gamma$ , Ultra-LEAF<sup>™</sup> Purified anti-mouse IFN- $\gamma$ , Brilliant Violet 711<sup>™</sup> anti-mouse IFN- $\gamma$ , Brilliant Violet 785<sup>™</sup> anti-mouse IFN- $\gamma$ , Brilliant Violet 605<sup>™</sup> anti-mouse IFN- $\gamma$ , Brilliant Violet 510<sup>™</sup> anti-mouse IFN- $\gamma$ , Purified anti-mouse IFN- $\gamma$  (Maxpar<sup>®</sup> Ready), PE/Dazzle<sup>™</sup> 594 anti-mouse IFN- $\gamma$ , Alexa Fluor<sup>®</sup> 700 anti-mouse IFN- $\gamma$ , APC/Cyanine7 anti-mouse IFN- $\gamma$ , GolnVivo<sup>™</sup> Purified anti-mouse IFN- $\gamma$ , APC/Fire<sup>™</sup> 750 anti-mouse IFN- $\gamma$ , Spark NIR<sup>™</sup> 685 anti-mouse IFN- $\gamma$

## Product Data



PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587